Cat Allergy - Pipeline Review, H1 2012

Global Markets Direct, June 2012, Pages: 35

Cat Allergy – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Cat Allergy - Pipeline Review, H1 2012', provides an overview of the Cat Allergy therapeutic pipeline. This report provides information on the therapeutic development for Cat Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cat Allergy. 'Cat Allergy - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cat Allergy.
- A review of the Cat Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cat Allergy pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cat Allergy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cat Allergy pipeline depth and focus of Cat Allergy therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Cat Allergy Therapeutic Products under Development, Key Players in Cat Allergy Therapeutics, Cat Allergy Pipeline Overview, Cat Allergy Pipeline, Cat Allergy Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cat Allergy Overview
Therapeutics Development
An Overview of Pipeline Products for Cat Allergy
Cat Allergy Therapeutics under Development by Companies
Mid Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Cat Allergy Therapeutics – Products under Development by Companies
Companies Involved in Cat Allergy Therapeutics Development
ALK-Abello A/S
Circassia Holdings Ltd.
ImVisioN Therapeutics AG
Biomay AG
Cat Allergy – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ToleroMune Cat Allergy T Cell Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IVN201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cat Allergen Peptide Carrier Fusion Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cat Allergen RNA Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cat Allergen Hypoallergenic Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cat Allergy Therapeutics – Drug Profile Updates
Cat Allergy – Product Development Milestones
Featured News & Press Releases
Jun 13, 2011: Circassia's Rapid Four-Dose ToleroMune Treatment Maintains Significant Reduction In Allergy Symptoms During 12-Month Follow-up
Feb 01, 2011: Circassia's ToleroMune T-cell Vaccine Achieves Significant Reduction In Allergy Symptoms In Key Phase II Clinical Study
Jan 19, 2010: Circassia Extends Its Clinical-Stage Portfolio With Phase II Trials of T-cell Vaccines Against House Dust Mite And Cat Allergies
Nov 20, 2009: Circassia Announces Successful Results From Phase II Clinical Study Of ToleroMune Cat Allergy Therapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Cat Allergy, H1 2012
Products under Development for Cat Allergy – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
ALK-Abello A/S, H1 2012
Circassia Holdings Ltd., H1 2012
ImVisioN Therapeutics AG, H1 2012
Biomay AG, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Cat Allergy Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Cat Allergy, H1 2012
Products under Development for Cat Allergy – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Mid Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Allergies - Pipeline Review, H2 2012
• Peanut Allergy - Pipeline Review, H2 2012
• Pollen Allergy - Pipeline Review, H2 2012
• Peanut Allergy – Pipeline Review, H1 2013
• Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2012
• Eczema - Pipeline Review, H1 2013
• Allergic Conjunctivitis - Pipeline Review, H1 2013
• Dyslipidemia - Pipeline Review, H1 2013
• Alzheimer's Disease – Pipeline Review, H1 2013
• Polycystic Kidney Disease - Pipeline Review, H1 2013